Operating Income (Loss) of Dianthus Therapeutics, Inc. /DE/ from 31 Dec 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Dec 2016 to 31 Dec 2025.
  • Dianthus Therapeutics, Inc. /DE/ Operating Income (Loss) for the quarter ending 31 Dec 2025 was $69,541,000, a 118% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ Operating Income (Loss) for the twelve months ending 31 Dec 2025 was $177,933,000, a 75% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ annual Operating Income (Loss) for 2025 was $177,933,000, a 75% decline from 2024.
  • Dianthus Therapeutics, Inc. /DE/ annual Operating Income (Loss) for 2024 was $101,864,000, a 111% decline from 2023.
  • Dianthus Therapeutics, Inc. /DE/ annual Operating Income (Loss) for 2023 was $48,174,000, a 62% decline from 2022.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Dianthus Therapeutics, Inc. /DE/ Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $177,933,000 $69,541,000 -$37,625,000 -118% 01 Oct 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
Q3 2025 $140,308,000 $40,288,000 -$10,388,000 -35% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $129,920,000 $34,927,000 -$12,723,000 -57% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $117,197,000 $33,177,000 -$15,333,000 -86% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $101,864,000 $31,916,000 -$18,960,000 -146% 01 Oct 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
Q3 2024 $82,904,000 $29,900,000 -$14,141,000 -90% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $68,763,000 $22,204,000 -$10,428,000 -89% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $58,335,000 $17,844,000 -$10,161,000 -132% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $48,174,000 $12,956,000 -$33,422,000 -163% 01 Oct 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
Q3 2023 $14,752,000 $15,759,000 -$7,505,000 -91% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $7,247,000 $11,776,000 +$6,307,000 +35% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $13,554,000 $7,683,000 +$16,151,000 +68% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $29,705,000 $20,466,000 -$21,000,000 -51% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $8,705,000 $8,254,000 +$9,991,000 +55% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $18,696,000 $18,083,000 -$473,000 -2.7% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $18,223,000 $23,834,000 -$5,137,000 -27% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $13,086,000 $41,466,000 +$60,531,000 01 Oct 2021 31 Dec 2021 8-K 21 Dec 2023
Q3 2021 $73,617,000 $18,245,000 +$136,000 +0.74% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $73,753,000 $17,610,000 +$2,402,000 +12% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $76,155,000 $18,697,000 +$2,547,000 +12% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $78,702,000 $19,065,000 +$5,572,000 +23% 01 Oct 2020 31 Dec 2020 10-K 08 Mar 2022 2021 FY
Q3 2020 $84,274,000 $18,381,000 +$4,263,000 +19% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $88,537,000 $20,012,000 -$674,000 -3.5% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $87,863,000 $21,244,000 -$4,894,000 -30% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $82,969,000 $24,637,000 -$6,707,000 -37% 01 Oct 2019 31 Dec 2019 10-K 03 Mar 2020 2019 FY
Q3 2019 $76,262,000 $22,644,000 -$5,942,000 -36% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $70,320,000 $19,338,000 -$5,313,000 -38% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $65,007,000 $16,350,000 -$5,044,000 -45% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $59,963,000 $17,930,000 -$9,760,000 -119% 01 Oct 2018 31 Dec 2018 10-K 03 Mar 2020 2019 FY
Q3 2018 $50,203,000 $16,702,000 -$9,687,000 -138% 01 Jul 2018 30 Sep 2018 10-K 03 Mar 2020 2019 FY
Q2 2018 $40,516,000 $14,025,000 +$1,706,000 +11% 01 Apr 2018 30 Jun 2018 10-K 03 Mar 2020 2019 FY
Q1 2018 $42,222,000 $11,306,000 -$6,495,000 -135% 01 Jan 2018 31 Mar 2018 10-K 03 Mar 2020 2019 FY
Q4 2017 $35,727,000 $8,170,000 01 Oct 2017 31 Dec 2017 10-K 19 Mar 2019 2018 FY
Q3 2017 $7,015,000 01 Jul 2017 30 Sep 2017 10-K 19 Mar 2019 2018 FY
Q2 2017 $15,731,000 01 Apr 2017 30 Jun 2017 10-K 19 Mar 2019 2018 FY
Q1 2017 $4,811,000 01 Jan 2017 31 Mar 2017 10-K 19 Mar 2019 2018 FY

Dianthus Therapeutics, Inc. /DE/ Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $177,933,000 -$76,069,000 -75% 01 Jan 2025 31 Dec 2025 10-K 09 Mar 2026 2025 FY
2024 $101,864,000 -$53,690,000 -111% 01 Jan 2024 31 Dec 2024 10-K 09 Mar 2026 2025 FY
2023 $48,174,000 -$18,469,000 -62% 01 Jan 2023 31 Dec 2023 10-K 11 Mar 2025 2024 FY
2022 $29,705,000 -$16,619,000 -127% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $13,086,000 +$65,616,000 +83% 01 Jan 2021 31 Dec 2021 8-K 21 Dec 2023
2020 $78,702,000 +$4,267,000 +5.1% 01 Jan 2020 31 Dec 2020 10-K 08 Mar 2022 2021 FY
2019 $82,969,000 -$23,006,000 -38% 01 Jan 2019 31 Dec 2019 10-K 03 Mar 2021 2020 FY
2018 $59,963,000 -$24,236,000 -68% 01 Jan 2018 31 Dec 2018 10-K 03 Mar 2020 2019 FY
2017 $35,727,000 -$26,459,000 -285% 01 Jan 2017 31 Dec 2017 10-K 03 Mar 2020 2019 FY
2016 $9,268,000 01 Jan 2016 31 Dec 2016 10-K 19 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.